Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment
By Aditya Bhagchandani Published on June 24, 2025, 09:50 IST
Glenmark Pharmaceuticals has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its entry into the immuno-oncology space. This anti-PD-1 monoclonal antibody, developed by global oncology firm BeiGene (now BeOne Medicines), is approved for the treatment of advanced non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC).
The drug is designed to restore T-cell function and minimize off-target immune suppression, having shown strong efficacy and safety in global trials. Already approved in over 46 countries including the U.S. and EU, TEVIMBRA has been used in treating more than 1.5 million patients worldwide.
Glenmark's President Alok Malik stated that the company is committed to transforming cancer care in India by making cutting-edge immunotherapies accessible. The launch comes at a time when cancer incidence in India is sharply rising, especially NSCLC and ESCC which dominate their respective cancer types in the country.
This milestone aligns with Glenmark's broader ambition to build a globally benchmarked oncology portfolio, adding to its existing focus areas of respiratory and dermatology.
Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
33 minutes ago
- Business Wire
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson's Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of a $96.5 million Series D financing round led by a healthcare investor, with significant support from existing investors Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments (Cayman) Ltd., and Acorn Bioventures. The Company also announced the first patient has been dosed in the global Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in people with early Parkinson's disease (PD). 'The Series D financing represents further endorsement of Neuron23's industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU-411 to people with Parkinson's disease who are most likely to benefit from LRRK2 inhibition, increasing probability of success in the clinic and bringing the right therapy to the right patients,' said Nancy Stagliano, Ph.D., Chief Executive Officer of Neuron23. 'The dosing of the first patient in the NEULARK clinical trial marks a pivotal milestone in Parkinson's disease research. For the first time, we are using a precision medicine approach to identify and enroll patients with LRRK2-driven disease,' said Dr. Aaron Ellenbogen, a movement disorders neurologist, Medical Director at Quest Research Institute, and NEULARK study investigator. 'This trial's design, incorporating a unique digital biomarker to frequently monitor disease progression, enables us to capture exceptionally precise, real-time data on both motor and non-motor symptoms, offering unparalleled insights into how the disease evolves. With multiple innovative elements cohesively working together in the NEULARK trial, we're poised to take a significant step forward in the pursuit of effective treatments for Parkinson's disease.' The global Phase 2 NEULARK clinical trial (NCT06680830) is a randomized, double-blind, placebo-controlled study in people with early-stage, LRRK2-driven PD. The study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of orally administered NEU-411. The trial will enroll approximately 150 participants who will receive NEU-411 or placebo daily for a 52-week treatment period. The trial incorporates a smartphone equipped with proprietary software developed by Roche Information Solutions (RIS) that frequently measures PD symptoms such as movement and tremor, as well as non-motor symptoms such as cognition. The primary endpoint is the change from baseline in the Roche digital biomarker score compared to placebo. Secondary outcome measures include the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a widely recognized tool for evaluating Parkinson's symptoms. Neuron23 has partnered with Sano Genetics to streamline patient referrals and assist in the identification of people with PD who may be eligible to participate in the NEULARK clinical trial. Under a separate protocol, Sano is offering saliva test kits that can identify people with LRRK2-driven PD. Individuals identified will be referred to the nearest NEULARK clinical trial site for a complete eligibility evaluation and potential enrollment. More information can be found at About LRRK2's Role in Parkinson's Disease and NEU-411 Mutations in the LRRK2 gene are among the most common genetic causes of PD, affecting approximately 2% of people with the disease. Individuals who inherit gain-of-function mutations in LRRK2 are at higher risk of developing PD later in life. Importantly, there is a growing body of evidence that LRRK2 activity may play a role in a subset of the larger population of people without a family history of PD, known as idiopathic PD, suggesting that therapies targeting LRRK2 could be beneficial to a broader population than just individuals with rare, familial LRRK2 mutations. Neuron23 has identified single-nucleotide polymorphisms (SNPs) – variations in an individual's DNA sequence – that are predicted to drive LRRK2 overactivity in up to 30% of people with idiopathic PD. People with PD who have these SNPs, together with those who have LRRK2 gene mutations, make up the population collectively referred to as LRRK2-driven PD and represent who Neuron23 believes is most likely to benefit from LRRK2 inhibition. NEU-411 is a potent, highly selective and brain-penetrant oral LRRK2 inhibitor with best-in-class potential. By specifically inhibiting the overactive LRRK2 kinase pathway, NEU-411 aims to address an underlying cause of disease progression in people with LRRK2-driven PD, offering a more precise and potentially more effective approach compared to existing treatment options that only address some symptoms of PD. About Parkinson's Disease Parkinson's disease (PD) is a brain disorder that causes irregular movements, such as shaking, stiffness and difficulty with balance and coordination. Symptoms usually begin gradually and worsen over time. As the disease progresses, people may have difficulty walking and talking. Additional symptoms can include mental and behavioral changes, such as sleep problems, depression, memory difficulties and fatigue. Some cases of PD appear to be hereditary, and a few cases can be traced to specific genetic mutations. Currently, there is no available cure or therapy that impacts underlying PD progression, and treatment options are only used to alleviate some symptoms. About Neuron23® Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA. For more information, please visit or follow us on LinkedIn and X (formerly Twitter).
Business Wire
33 minutes ago
- Business Wire
The AZEK ® Company Announces Sale of Commercial Segment's Scranton Products Business to Sky Island Capital
CHICAGO--(BUSINESS WIRE)-- The AZEK Company Inc. (NYSE: AZEK) ("AZEK" or the 'Company'), the industry-leading manufacturer of beautiful, low-maintenance and environmentally sustainable outdoor living products, including TimberTech® Decking and Railing, AZEK® and Versatex® Trim, and StruXure® pergolas, today announced the completion of its divestiture of Scranton Products, a division of its Commercial segment, to Sky Island Capital, a private equity firm focused on partnering exclusively with privately-held manufacturing companies. 'Today marks an exciting new chapter for the Scranton Products team,' said Jonathan Skelly, President, Residential and Commercial at The AZEK Company. 'We believe Sky Island brings the vision and focus needed to accelerate Scranton Products' growth and success in the commercial space. With a legacy dating back to 1978, Scranton Products has long been a market leader in high-quality HDPE plastic solutions. We are deeply grateful for their contributions to our business and confident they will continue to lead the industry in durable bathroom partitions and lockers.' Rob Donlon, who has been with Scranton Products for over 20 years and currently serves as Vice President and General Manager, will remain in his leadership role as the business transitions under new ownership. His deep experience and commitment to Scranton Products will continue to guide the team through this next chapter. 'We're proud to join forces with the Scranton Products team,' said Jack Waterstreet, Managing Partner at Sky Island Capital. 'Their track record and market reputation speak for themselves, and we look forward to helping the company unlock its next phase of growth.' Sky Island Capital serves as a resource and strategic partner of manufacturing companies with one goal in mind – growth. Their team has worked with more than 50 manufacturing companies, not only as strategic partners, but also as day-to-day operators. They work in a variety of sectors, including advanced materials, industrial products, and technology. Scranton Products will continue to operate from its current location, ensuring continuity for its employees, customers, and partners. William Blair & Company acted as financial advisor, and Latham & Watkins LLP acted as legal advisor, to The AZEK Company in the sale of Scranton Products to Sky Island Capital. For more information on Scranton Products, visit About The AZEK® Company The AZEK Company Inc. (NYSE: AZEK) is the industry-leading designer and manufacturer of beautiful, low maintenance and environmentally sustainable outdoor living products, including TimberTech® decking and railing, AZEK® and Versatex® Trim, and StruXure® pergolas. Consistently awarded and recognized as the market leader in innovation, quality, aesthetics and sustainability, our products are made from up to 85% recycled material and primarily replace wood on the outside of homes, providing a long-lasting, eco-friendly, and stylish solution to consumers. Leveraging the talents of its approximately 2,000 employees and the strength of relationships across its value chain, The AZEK Company is committed to accelerating the use of recycled material in the manufacturing of its innovative products, keeping hundreds of millions of pounds of waste and scrap out of landfills each year, and revolutionizing the industry to create a more sustainable future. The AZEK Company has recently been named one of America's Most Responsible Companies by Newsweek, a Top Workplace by the Chicago Tribune and U.S. News and World Report, one of Barron's 100 Most Sustainable U.S. Companies, one of TIME's World's Best Companies in Sustainable Growth for 2025, and celebrated in Fast Company's 2024 Brands That Matter list, where TimberTech was highlighted as a benchmark brand. Headquartered in Chicago, Illinois, the company operates manufacturing and recycling facilities in Ohio, Pennsylvania, Idaho, Georgia, Nevada, New Jersey, Michigan, Minnesota and Texas.
Business Wire
an hour ago
- Business Wire
Energous Introduces Battery-Free e-Sense Tag, Establishing First End-to-End Wireless Power Platform for the Ambient IoT
SAN JOSE, Calif.--(BUSINESS WIRE)--Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT), a leader in over-the-air (OTA) wireless power networks, today announced the launch of the e-Sense tag, a battery-free, maintenance-free wireless sensor for location and temperature monitoring in retail, supply chain, and logistics environments. Ambient IoT is reshaping how the physical world connects. With the introduction of the e-Sense tag, Energous now offers a complete ambient IoT platform consisting of wirelessly-powered, battery-free sensors, RF-based energy transmitters, and cloud-based monitoring software. This integrated system enables uninterrupted, real-time visibility across supply chains without relying on batteries, manual maintenance, or conventional wired infrastructure. The e-Sense tag operates using energy harvested from Energous' wireless power network. It features a compact 4x5 cm form factor; is fully encapsulated and waterproof; and is engineered for reuse in high-volume, operationally-complex environments. The tag continuously reports temperature and location data to Energous' cloud platform and is optimized for retail, transportation, and cold chain applications. It is exclusively compatible with Energous PowerBridge ® transmitters and offers cost savings benefits compared to conventional battery-powered alternatives. 'Adding e-Sense to our product portfolio positions Energous as a full-stack provider of wirelessly powered sensing and infrastructure solutions for tracking interconnected devices in the ambient IoT ecosystem,' said Mallorie Burak, CEO and CFO of Energous. 'This tag eliminates both the maintenance burden and environmental impact of batteries while providing enterprise-grade sensing and connectivity at scale – enabling businesses to bring intelligence to products, pallets, and packages in their supply chains at scale.' Sensor data from the e-Sense tag is transmitted to e-Compass, the company's secure, cloud-based asset intelligence platform. The platform offers real-time monitoring, device management, zoning, reporting, and support for historical data analysis. Built on AWS IoT Core, e-Compass supports enterprise deployments with tools for regulatory compliance, process optimization, and decision-making based on real-time environmental conditions. The e-Sense tag further realizes the company's vision for an end-to-end ambient IoT solution. Together with Energous transmitters and e-Compass cloud software, it forms a system architecture that delivers persistent visibility, energy autonomy, and operational efficiency across large, distributed supply chains. Ambient IoT enables a new class of connected devices that are smaller, lower-cost, and more sustainable than traditional, battery-powered sensor technologies. As global enterprises scale deployments to improve traceability, compliance, and automation, wireless power is becoming an essential layer of infrastructure. Energous provides the certified technology, deployment experience, and platform integration required to support these initiatives. 'Ambient IoT is reshaping how the physical world connects,' concluded Burak. 'The launch of e-Sense completes our end-to-end solution – bringing together wireless power, intelligent sensing, and cloud-based visibility into a single, scalable platform. It reflects our continued commitment to delivering the wireless, battery-less infrastructure required to support the real-time supply chain visibility that will transform industries.' About Energous Wireless Power Solutions Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT) is pioneering scalable, over-the-air (OTA) wireless power networks that enable unprecedented levels of visibility, control, and intelligent business automation. The company's wireless power transmitter and receiver technologies deliver continuous access to wireless power, helping drive a new generation of battery-free devices for asset and inventory tracking and management—from retail sensors, electronic shelf labels, and asset trackers to air quality monitors, motion detectors, and more. For more information, visit or follow on LinkedIn. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements may describe our future plans and expectations and are based on the current beliefs, expectations and assumptions of Energous. These statements generally use terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'could,' 'seek,' 'intend,' 'plan,' 'estimate,' 'anticipate' or similar terms. Examples of forward-looking statements in this release include but are not limited to statements about the future of the global wireless charging industry and statements about our technology and its expected functionality. Factors that could cause actual results to differ from current expectations include: uncertain timing of necessary regulatory approvals; timing of customer product development and market success of customer products; our dependence on distribution partners; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K as filed with the Securities and Exchange Commission (SEC), any subsequently filed quarterly reports on Form 10-Q as well as in other documents that may have been subsequently filed by Energous, from time to time, with the SEC, in evaluating our forward-looking statements. In addition, any forward-looking statements represent Energous' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Energous does not assume any obligation to update any forward-looking statements unless required by law.
